BIODEXA PHARMACEUTICALS PLC

Company Number		09216368
Company ID Number		09216368
Date formed		2014-09-12
Country		WALES
Origin Country		United Kingdom
Type		Public Limited Company
CompanyStatus		Active
Lastest accounts		31/12/2023
Account next due		30/06/2025
Latest return		12/09/2015
Return next due		10/10/2016
Type of accounts		GROUP
VAT Number /Sales tax ID		GB203981417

Is this data useful to you?

If you found the data here useful, PLEASE HELP US. We are a start-up and believe in making information freely available. Please DONATE to help.
Alternatively by linking to us, posting on twitter, facebook and linkedin about us and generally spreading the word, you'll help us to grow. Our vision is to provide high quality data about the activities of all the companies in the world and where possible make it free to use and view. Finding and integrating data from thousands of data sources is time consuming and needs lots of effort. By simply spreading the word about us, you will help us.

Companies with same name BIODEXA PHARMACEUTICALS PLC

The following companies were found which have the same name as BIODEXA PHARMACEUTICALS PLC. These may be the same company in different jurisdictions

		Registered address	Last known status	Formation date
	BIODEXA PHARMACEUTICALS (WALES) LIMITED	1 CASPIAN POINT CASPIAN WAY CARDIFF CF10 4DQ	Active	Company formed on the 2003-10-10

Company Officers of BIODEXA PHARMACEUTICALS PLC

Current Directors

Officer	Role	Date Appointed
NICHOLAS ROBBINS-CHERRY	Company Secretary	2014-11-27
CRAIG RICHARD COOK	Director	2018-06-01
SIJMEN DE VRIES	Director	2014-11-13
JOHN JOSEPH JOHNSTON	Director	2014-11-13
MICHELE LUZI	Director	2014-11-13
PAVLO PROTOPAPA	Director	2014-11-13
NICHOLAS JOHN ROBBINS-CHERRY	Director	2014-09-12
ROLF STAHEL	Director	2014-11-13
SIMON TURTON	Director	2014-12-02

Previous Officers

Officer	Role	Date Appointed	Date Resigned
JAMES NEIL PHILLIPS	Director	2014-09-12	2018-05-31
JEFFREY JOHN BROWN	Director	2014-11-13	2015-04-30
KEITH KENDALL	Director	2014-11-13	2014-12-08
STEVEN ROSS PRESS	Director	2014-11-13	2014-12-08

Related Directorships

Officer	Related Company	Role	Date Appointed	Role Status	Incorporation date	Company Status
CRAIG RICHARD COOK	BIODEXA LTD	Director	2018-06-01	CURRENT	2000-10-27	Active
CRAIG RICHARD COOK	BIODEXA PHARMACEUTICALS (WALES) LIMITED	Director	2018-06-01	CURRENT	2003-10-10	Active
CRAIG RICHARD COOK	SEDATEUK LTD	Director	2016-01-11	CURRENT	2014-12-02	Active
CRAIG RICHARD COOK	SHAWLMIST LIMITED	Director	2010-10-05	CURRENT	1984-06-26	Active
CRAIG RICHARD COOK	SWISSCARE HEALTH LIMITED	Director	2010-05-05	CURRENT	2010-05-05	Active
JOHN JOSEPH JOHNSTON	JOHNSTON ASSET MANAGEMENT LTD	Director	2013-05-15	CURRENT	2013-05-15	Active
MICHELE LUZI	VIESVI LIMITED	Director	2014-09-18	CURRENT	2014-09-18	Active
MICHELE LUZI	YELLOW SKY PUBLISHING LIMITED	Director	2013-02-22	CURRENT	2013-02-22	Dissolved 2015-08-18
MICHELE LUZI	ASHWICK DEVELOPMENTS LIMITED	Director	2012-09-18	CURRENT	2012-07-23	Active
MICHELE LUZI	ASHWICK PROJECTS LIMITED	Director	2012-07-23	CURRENT	2012-04-16	Active
MICHELE LUZI	PROJECT 99 LIMITED	Director	2010-06-29	CURRENT	2010-06-29	Active - Proposal to Strike off
MICHELE LUZI	RMD TRAFFORD HOUSE 2000 LIMITED	Director	2010-02-05	CURRENT	2010-02-04	Dissolved 2016-09-16
NICHOLAS JOHN ROBBINS-CHERRY	BIODEXA LTD	Director	2015-03-13	CURRENT	2000-10-27	Active
NICHOLAS JOHN ROBBINS-CHERRY	CURA VACCINES LTD	Director	2014-10-21	CURRENT	2007-02-21	Dissolved 2016-01-26
ROLF STAHEL	AMPHA LIMITED	Director	2016-12-08	CURRENT	2016-09-23	Active
ROLF STAHEL	CHESYL PHARMA LTD	Director	2003-09-24	CURRENT	2003-08-20	Liquidation

More director information

Corporation Filing History

Companies House Filing History

This is a record of the public documents (corporate filing) lodged from Companies House where the company has filed annual returns and other statutory filing documents. Examples of documents filed include: change of registered office, accounts filing, director/officer appointments & resignations, changes in share capital, shareholder members lists etc.

Date	Document Type	Document Description
2024-11-05		16/10/24 STATEMENT OF CAPITAL GBP 11480461.34
2024-11-05		17/10/24 STATEMENT OF CAPITAL GBP 11691111.34
2024-11-05		23/10/24 STATEMENT OF CAPITAL GBP 11723711.34
2024-11-05		CONFIRMATION STATEMENT MADE ON 23/10/24, WITH NO UPDATES
2024-09-24		12/07/24 STATEMENT OF CAPITAL GBP 8851394.54
2024-09-24		22/07/24 STATEMENT OF CAPITAL GBP 10871717.74
2024-09-24		08/08/24 STATEMENT OF CAPITAL GBP 10922781.34
2024-06-27		GROUP OF COMPANIES' ACCOUNTS MADE UP TO 31/12/23
2024-06-20		Resolutions passed:<ul><li>Resolution passed removal of pre-emption<li>Resolution Company business / appoint directors 13/06/2024</ul>
2024-06-20		Resolutions passed:<ul><li>Resolution passed removal of pre-emption<li>Resolution Company business / appoint directors 13/06/2024<li>Resolution on securities</ul>
2024-06-12		21/05/24 STATEMENT OF CAPITAL GBP 7358911.34
2024-06-12		22/05/24 STATEMENT OF CAPITAL GBP 7447608.94
2024-06-12		24/05/24 STATEMENT OF CAPITAL GBP 8689435.34
2024-05-01		Second filing of capital allotment of shares GBP6,621,355.340
2024-05-01		Second filing of capital allotment of shares GBP6,611,355.340
2024-04-24		02/04/24 STATEMENT OF CAPITAL GBP 6969112.54
2024-03-26		14/02/24 STATEMENT OF CAPITAL GBP 6611355.34
2024-03-26		14/02/24 STATEMENT OF CAPITAL GBP 6621355.34
2024-03-22		23/02/24 STATEMENT OF CAPITAL GBP 6763126.54
2023-10-18		01/09/23 STATEMENT OF CAPITAL GBP 5429122.14
2023-10-04		24/07/23 STATEMENT OF CAPITAL GBP 5425322.14
2023-07-19		Sub-division of shares on 2023-06-14
2023-07-18		Change of share class name or designation
2023-07-11		15/06/23 STATEMENT OF CAPITAL GBP 5277806.44
2023-07-07		GROUP OF COMPANIES' ACCOUNTS MADE UP TO 31/12/22
2023-06-30		Memorandum articles filed
2023-06-30		Resolutions passed:<ul><li>Resolution variation to share rights</ul>
2023-06-30		Resolutions passed:<ul><li>Resolution variation to share rights<li>Resolution passed adopt articles</ul>
2023-06-30		Resolutions passed:<ul><li>Resolution passed removal of pre-emption</ul>
2023-06-30		Resolutions passed:<ul><li>Resolution passed removal of pre-emption<li>Resolution Company business/ appointment of director/ appointment of auditors 14/06/2023</ul>
2023-06-30		Resolutions passed:<ul><li>Resolution passed removal of pre-emption<li>Resolution Company business/ appointment of director/ appointment of auditors 14/06/2023<li>Resolution on securities</ul>
2023-06-26		06/06/23 STATEMENT OF CAPITAL GBP 5277181.44
2023-06-23		09/05/23 STATEMENT OF CAPITAL GBP 2933589.24
2023-06-23		26/05/23 STATEMENT OF CAPITAL GBP 5147181.44
2023-05-17		Memorandum articles filed
2023-05-03		19/04/23 STATEMENT OF CAPITAL GBP 2892589.24
2023-04-27		30/03/23 STATEMENT OF CAPITAL GBP 1819898.74
2023-04-03		Consolidation of shares on
2023-04-03		Resolutions passed:<ul><li>Resolution on securities<li>Resolution passed removal of pre-emption</ul>
2023-04-03		Resolutions passed:<ul><li>Resolution on securities<li>Resolution passed removal of pre-emption<li>Resolution variation to share rights<li>Resolution passed adopt articles</ul>
2023-03-28		24/03/23 STATEMENT OF CAPITAL GBP 1173347.74
2023-03-28		24/03/23 STATEMENT OF CAPITAL GBP 1173347.74
2023-03-27		Company name changed midatech pharma PLC\certificate issued on 27/03/23
2023-03-27		Company name changed midatech pharma PLC\certificate issued on 27/03/23
2023-02-16		15/02/23 STATEMENT OF CAPITAL GBP 1173347.738
2023-02-06		19/12/22 STATEMENT OF CAPITAL GBP 1108343.738
2023-01-25		Resolutions passed:<ul><li>Resolution on securities</ul>
2022-10-11		Resolutions passed:<ul><li>Resolution passed removal of pre-emption<li>Resolution on securities</ul>
2022-06-27	AP01	DIRECTOR APPOINTED DR STEPHEN BARRY PARKER
2022-06-27	TM01	APPOINTMENT TERMINATED, DIRECTOR ROLF STAHEL
2022-06-24	AA	GROUP OF COMPANIES' ACCOUNTS MADE UP TO 31/12/21
2022-05-13	SH01	22/03/22 STATEMENT OF CAPITAL GBP 1098469.413
2021-11-03	CS01	CONFIRMATION STATEMENT MADE ON 23/10/21, WITH NO UPDATES
2021-08-02	AD01	REGISTERED OFFICE CHANGED ON 02/08/21 FROM Oddfellows House 19 Newport Road Cardiff CF24 0AA Wales
2021-07-28	RES10	Resolutions passed: Resolution of allotment of securities Resolution of removal of pre-emption rights Resolution alteration of articles
2021-07-28	MEM/ARTS	ARTICLES OF ASSOCIATION
2021-07-15	SH01	06/07/21 STATEMENT OF CAPITAL GBP 1098469.387
2021-07-13	AA	GROUP OF COMPANIES' ACCOUNTS MADE UP TO 31/12/20
2021-06-30	SH01	19/02/21 STATEMENT OF CAPITAL GBP 1063381.667
2020-11-19	PSC08	Notification of a person with significant control statement
2020-11-06	CS01	CONFIRMATION STATEMENT MADE ON 23/10/20, WITH NO UPDATES
2020-11-06	PSC07	CESSATION OF A & B (HK) COMPANY LTD AS A PERSON OF SIGNIFICANT CONTROL
2020-10-08	SH01	30/09/20 STATEMENT OF CAPITAL GBP 1063074.852
2020-09-01	RP04CS01
2020-09-01	AA	GROUP OF COMPANIES' ACCOUNTS MADE UP TO 31/12/19
2020-08-26	SH01	21/08/20 STATEMENT OF CAPITAL GBP 1063049.852
2020-08-22	SH02	Consolidation of shares on 2020-03-02
2020-08-13	RP04SH01	Second filing of capital allotment of shares GBP1,060,549.852
2020-08-12	SH01	03/08/20 STATEMENT OF CAPITAL GBP 1039253.557
2020-08-03	SH01	22/05/20 STATEMENT OF CAPITAL GBP 139253.657001
2020-04-16	TM01	APPOINTMENT TERMINATED, DIRECTOR CRAIG RICHARD COOK
2020-04-02	TM01	APPOINTMENT TERMINATED, DIRECTOR FREDERIC DUCHESNE
2020-03-13	RES12	Resolution of varying share rights or name
2020-03-12	SH02	Consolidation of shares on 2020-03-02
2020-03-12	SH01	02/03/20 STATEMENT OF CAPITAL GBP 123496.08
2020-03-02	SPLR	London Stock Exchange corporate action. Reverse Stock Split/Change in Nominal Value of ORD GBP0.00005 for COAF: UK600128728Y2020 ASIN: GB00BRTL9B63
2020-02-18	SPLR	London Stock Exchange corporate action. Reverse Stock Split/Change in Nominal Value of ORD GBP0.00005 for COAF: UK600128728Y2020 ASIN: GB00BRTL9B63
2020-02-14	RP04SH01	Second filing of capital allotment of shares GBP120,496.08
2020-02-12	SPLR	London Stock Exchange corporate action. Reverse Stock Split/Change in Nominal Value of ORD GBP0.00005 for COAF: UK600128728Y2020 ASIN: GB00BRTL9B63
2020-02-07	SH01	07/10/19 STATEMENT OF CAPITAL GBP 2147039.767323
2019-11-08	CS01	CONFIRMATION STATEMENT MADE ON 23/10/19, WITH UPDATES
2019-11-08	PSC02	Notification of Cms Medical Hong Kong Ltd as a person with significant control on 2019-02-26
2019-11-05	PSC09	Withdrawal of a person with significant control statement on 2019-11-05
2019-09-10	AP01	DIRECTOR APPOINTED MR STEPHEN ANTHONY STAMP
2019-09-10	AP03	Appointment of Mr Stephen Anthony Stamp as company secretary on 2019-09-09
2019-09-10	TM01	APPOINTMENT TERMINATED, DIRECTOR NICHOLAS JOHN ROBBINS-CHERRY
2019-09-10	TM02	Termination of appointment of Nicholas Robbins-Cherry on 2019-09-09
2019-08-07	AP01	DIRECTOR APPOINTED MR FREDERIC DUCHESNE
2019-07-23	AA	GROUP OF COMPANIES' ACCOUNTS MADE UP TO 31/12/18
2019-07-04	RES10	Resolutions passed: Resolution of allotment of securities Resolution of removal of pre-emption rights Resolution to purchase shares Company business 19/06/2019
2019-04-18	SH01	01/08/18 STATEMENT OF CAPITAL GBP 2146999.165001
2019-04-18	AP01	DIRECTOR APPOINTED DR HUAIZHENG PENG
2019-04-18	TM01	APPOINTMENT TERMINATED, DIRECTOR JOHN JOSEPH JOHNSTON
2019-03-20	RES11	Resolutions passed: Resolution of removal of pre-emption rights Resolutions Resolution of allotment of securities
2019-03-19	SH01	26/02/19 STATEMENT OF CAPITAL GBP 2146999.100001
2019-02-28	AD01	REGISTERED OFFICE CHANGED ON 28/02/19 FROM 65 Innovation Drive, Milton Park Milton Abingdon Oxfordshire OX14 4RQ
2019-02-04	RHDI	London Stock Exchange corporate action. Intermediate Securities Distribution of ORD GBP0.00005 for COAF: UK600117979Y2019 ASIN: GB00BRTL9B63
2019-02-04	PRIO	London Stock Exchange corporate action. Priority Issue of NEW ORD GBP0.00005 (SUB SHS CLAIMS PURP) for COAF: UK600118103Y2019 ASIN: GB00BF559Q37
2019-02-04	PRIO	London Stock Exchange corporate action. Priority Issue of NEW ORD GBP0.00005 (EXCESS APPS) for COAF: UK600118104Y2019 ASIN: GB00BF559R44
2019-01-29	RHDI	London Stock Exchange corporate action. Intermediate Securities Distribution of ORD GBP0.00005 for COAF: UK600117979Y2019 ASIN: GB00BRTL9B63
2018-12-03	MR04	STATEMENT OF SATISFACTION OF A CHARGE / FULL / CHARGE CODE 092163680001
2018-11-16	MR04	STATEMENT OF SATISFACTION OF A CHARGE / FULL / CHARGE CODE 092163680003
2018-11-06	CS01	CONFIRMATION STATEMENT MADE ON 23/10/18, WITH UPDATES
2018-11-06	MR04	STATEMENT OF SATISFACTION OF A CHARGE / FULL / CHARGE CODE 092163680002
2018-10-25	RES13	Resolutions passed: Sale agreement 15/10/2018
2018-08-06	AA	GROUP OF COMPANIES' ACCOUNTS MADE UP TO 31/12/17
2018-06-14	AP01	DIRECTOR APPOINTED DR CRAIG RICHARD COOK
2018-06-14	TM01	APPOINTMENT TERMINATED, DIRECTOR JAMES NEIL PHILLIPS
2018-02-05	LATEST SOC	05/02/18 STATEMENT OF CAPITAL;GBP 102442.465401
2018-02-05	SH01	07/11/17 STATEMENT OF CAPITAL GBP 102442.465401
2018-02-05	SH01	16/10/17 STATEMENT OF CAPITAL GBP 102442.465401
2018-02-05	SH01	19/05/17 STATEMENT OF CAPITAL GBP 102442.465401
2018-02-05	CS01	CONFIRMATION STATEMENT MADE ON 23/10/17, WITH UPDATES
2018-01-04	MR01	REGISTRATION OF A CHARGE / CHARGE CODE 092163680003
2018-01-04	MR01	REGISTRATION OF A CHARGE / CHARGE CODE 092163680004
2018-01-03	MR01	REGISTRATION OF A CHARGE / CHARGE CODE 092163680002
2017-10-20	RES11	Resolutions passed: Resolution of removal of pre-emption rights Resolution of allotment of securities
2017-10-20	RES10	AUTHORISED ALLOTMENT OF SHARES AND DEBENTURES
2017-10-20	RES10	AUTHORISED ALLOTMENT OF SHARES AND DEBENTURES
2017-10-16	PRIO	London Stock Exchange corporate action. Priority Issue of NEW ORD GBP0.00005 (SUB SHS CLAIMS PURP) for COAF: UK600104531Y2017 ASIN: GB00BD7Y4479
2017-10-16	PRIO	London Stock Exchange corporate action. Priority Issue of NEW ORD GBP0.00005 (EXCESS) for COAF: UK600104532Y2017 ASIN: GB00BD7Y4818
2017-09-28	RHDI	London Stock Exchange corporate action. Intermediate Securities Distribution of ORD GBP0.00005 for COAF: UK600104530Y2017 ASIN: GB00BRTL9B63
2017-09-28	PRIO	London Stock Exchange corporate action. Priority Issue of NEW ORD GBP0.00005 (SUB SHS CLAIMS PURP) for COAF: UK600104531Y2017 ASIN: GB00BD7Y4479
2017-09-28	PRIO	London Stock Exchange corporate action. Priority Issue of NEW ORD GBP0.00005 (EXCESS) for COAF: UK600104532Y2017 ASIN: GB00BD7Y4818
2017-09-13	LATEST SOC	13/09/17 STATEMENT OF CAPITAL;GBP 102436.072801
2017-09-13	CS01	CONFIRMATION STATEMENT MADE ON 12/09/17, WITH UPDATES
2017-07-24	PSC08	Notification of a person with significant control statement
2017-06-15	AA	GROUP OF COMPANIES' ACCOUNTS MADE UP TO 31/12/16
2017-02-27	MR01	REGISTRATION OF A CHARGE / CHARGE CODE 092163680001
2017-01-13	LATEST SOC	13/01/17 STATEMENT OF CAPITAL;GBP 102435.97
2017-01-13	SH01	28/10/16 STATEMENT OF CAPITAL GBP 102435.97
2016-11-17	CS01	CONFIRMATION STATEMENT MADE ON 12/09/16, WITH NO UPDATES
2016-11-17	RES10	Resolutions passed: Resolution of allotment of securities
2016-10-28	PRIO	London Stock Exchange corporate action. Priority Issue of NEW ORD GBP0.00005 (SUB SHS-CLAIMS PURP) for COAF: UK600094784Y2016 ASIN: GB00BYYHDN88
2016-10-28	PRIO	London Stock Exchange corporate action. Priority Issue of NEW ORD GBP0.00005 (EXCESS) for COAF: UK600094785Y2016 ASIN: GB00BYYHDP03
2016-10-11	RHDI	London Stock Exchange corporate action. Intermediate Securities Distribution of ORD GBP0.00005 for COAF: UK600094783Y2016 ASIN: GB00BRTL9B63
2016-10-11	PRIO	London Stock Exchange corporate action. Priority Issue of NEW ORD GBP0.00005 (SUB SHS-CLAIMS PURP) for COAF: UK600094784Y2016 ASIN: GB00BYYHDN88
2016-10-11	PRIO	London Stock Exchange corporate action. Priority Issue of NEW ORD GBP0.00005 (EXCESS) for COAF: UK600094785Y2016 ASIN: GB00BYYHDP03
2016-07-14	LATEST SOC	14/07/16 STATEMENT OF CAPITAL;GBP 1001676.62
2016-07-14	SH01	27/06/16 STATEMENT OF CAPITAL GBP 1001676.62
2016-07-06	AA	GROUP OF COMPANIES' ACCOUNTS MADE UP TO 31/12/15
2016-05-25	RES09	AUTHORITY- PURCHASE SHARES OTHER THAN FROM CAPITAL
2016-05-25	RES10	AUTHORISED ALLOTMENT OF SHARES AND DEBENTURES
2016-04-12	LATEST SOC	12/04/16 STATEMENT OF CAPITAL;GBP 1001674.37
2016-04-12	SH01	23/12/15 STATEMENT OF CAPITAL GBP 1001674.37
2016-04-12	SH01	02/12/15 STATEMENT OF CAPITAL GBP 1001663.14
2015-11-13	LATEST SOC	13/11/15 STATEMENT OF CAPITAL;GBP 1001392.038
2015-11-13	SH01	23/09/15 STATEMENT OF CAPITAL GBP 1001392.038
2015-09-23	AR01	12/09/15 FULL LIST
2015-05-15	AA	GROUP OF COMPANIES' ACCOUNTS MADE UP TO 31/12/14
2015-05-14	TM01	APPOINTMENT TERMINATED, DIRECTOR JEFFREY BROWN
2015-03-31	AD01	REGISTERED OFFICE CHANGED ON 31/03/2015 FROM MILTON PARK INNOVATION CENTRE 99 PARK DRIVE MILTON ABINGDON OXFORDSHIRE OX14 4RY
2015-03-24	AP01	DIRECTOR APPOINTED MR SIMON TURTON
2015-01-28	TM01	APPOINTMENT TERMINATED, DIRECTOR STEVEN PRESS
2015-01-28	TM01	APPOINTMENT TERMINATED, DIRECTOR KEITH KENDALL
2014-12-22	RES01	ADOPT ARTICLES 02/12/2014
2014-12-22	LATEST SOC	22/12/14 STATEMENT OF CAPITAL;GBP 1001390.713
2014-12-22	SH01	02/12/14 STATEMENT OF CAPITAL GBP 1001390.713
2014-12-19	SH02	CONSOLIDATION SUB-DIVISION 28/11/14
2014-12-19	RES13	SUB DIVISION OF SHARES 28/11/2014
2014-12-19	RES10	AUTHORISED ALLOTMENT OF SHARES AND DEBENTURES
2014-12-19	AP01	DIRECTOR APPOINTED MR JOHN JOSEPH JOHNSTON
2014-12-19	SH08	NOTICE OF NAME OR OTHER DESIGNATION OF CLASS OF SHARES
2014-12-19	SH08	NOTICE OF NAME OR OTHER DESIGNATION OF CLASS OF SHARES
2014-12-19	SH01	28/11/14 STATEMENT OF CAPITAL GBP 1000500.2686
2014-12-17	AA01	CURRSHO FROM 30/09/2015 TO 31/12/2014
2014-12-03	AP01	DIRECTOR APPOINTED JEFFREY JOHN BROWN
2014-12-03	AP01	DIRECTOR APPOINTED PAVLO PROTOPAPA
2014-12-03	AP01	DIRECTOR APPOINTED STEVEN ROSS PRESS
2014-12-03	AP01	DIRECTOR APPOINTED MR MICHELE LUZI
2014-12-03	AP01	DIRECTOR APPOINTED KEITH KENDALL
2014-12-03	AP01	DIRECTOR APPOINTED DR SIJMEN DE VRIES
2014-12-03	AP01	DIRECTOR APPOINTED MR ROLF STAHEL
2014-12-03	SH02	SUB-DIVISION 13/11/14
2014-12-03	RES13	SUBDIVISION 13/11/2014
2014-12-03	RES01	ADOPT ARTICLES 13/11/2014
2014-12-03	SH01	13/11/14 STATEMENT OF CAPITAL GBP 1000437.4330
2014-11-28	AD01	REGISTERED OFFICE CHANGED ON 28/11/2014 FROM 8 CLIFFORD STREET LONDON W1S 2LQ UNITED KINGDOM
2014-11-27	MAR	REREGISTRATION MEMORANDUM AND ARTICLES
2014-11-27	AUDS	AUDITORS' STATEMENT
2014-11-27	CERT5	CERTIFICATE OF REREGISTRATION FROM PRIVATE TO PLC
2014-11-27	RES02	REREG PRI TO PLC; RES02 PASS DATE:27/11/2014
2014-11-27	RR01	APPLICATION BY A PRIVATE COMPANY FOR RE-REGISTRATION AS A PUBLIC COMPANY
2014-11-27	BS	BALANCE SHEET
2014-11-27	AUDR	AUDITORS' REPORT
2014-09-12	NEWINC	CERTIFICATE OF INCORPORATION GENERAL COMPANY DETAILS & STATEMENTS OF; OFFICERS, CAPITAL & SHAREHOLDINGS, GUARANTEE, COMPLIANCE MEMORANDUM OF ASSOCIATION ARTICLES OF ASSOCIATION

Industry Information

SIC/NAIC Codes

72 - Scientific research and development

721 - Research and experimental development on natural sciences and engineering

72110 - Research and experimental development on biotechnology

Licences & Regulatory approval

We could not find any licences issued to BIODEXA PHARMACEUTICALS PLC or authorisation from an industry specific regulator to operate. These may not be required.

Share this page on Facebook

Risks

Legal Notices

No legal notices or events such as winding-up orders or proposals to strike-off have been issued

Fines / Sanctions

No fines or sanctions have been issued against BIODEXA PHARMACEUTICALS PLC

Liabilities

Mortgages / Charges

Total # Mortgages/Charges	4
Mortgages/Charges outstanding	0
Mortgages Partially Satisifed	0
Mortgages Satisfied/Paid	4

Details of Mortgagee Charges

We do not yet have the details of BIODEXA PHARMACEUTICALS PLC's previous or outstanding mortgage charges.

Intangible Assets

Patents

We have not found any records of BIODEXA PHARMACEUTICALS PLC registering or being granted any patents

Domain Names

We do not have the domain name information for BIODEXA PHARMACEUTICALS PLC

Trademarks

Trademark assignments by BIODEXA PHARMACEUTICALS PLC

		Date	Trademark ID	Reg Mark ID	Assigned to	Location	Reason
	USPTO	2017-12-29	US85508739		INTELLICHECK MOBILISA, INC.	DELAWARE	SECURITY INTEREST

Income

Government Income

We have not found government income sources for BIODEXA PHARMACEUTICALS PLC. This could be because the transaction value was below £ 500 with local government or below £ 25,000 for central government. We have found 8,000 supplier to government that are UK companies so approx 0.2% of companies listed on Datalog supply to government.

The top companies supplying to UK government with the same SIC code (72110 - Research and experimental development on biotechnology) as BIODEXA PHARMACEUTICALS PLC are:

Outgoings

Business Rates/Property Tax

No properties were found where BIODEXA PHARMACEUTICALS PLC is liable for the business rates / property tax. This could be for a number of reasons.

The council hasnt published the data
We havent found or been able to process the councils data
The company is part of a group of companies and another company in the group is liable for business rates
The registered office may be a residential address which does not have a commercial designation. If the business is run from home then it won't be a commercial property and hence won't be liable for business rates.
Serviced offices are increasingly popular and therefore a business may not be paying business rates directly - the building owner is and this is incorporated in the office rental charge.

Import/Export of Goods

Goods imported/exported by BIODEXA PHARMACEUTICALS PLC

Date	Import Code	Imported Goods classification description
2018-12-00	29241900	Acyclic amides, incl. acyclic carbamates, and their derivatives, and salts thereof (excl. meprobamate [INN], fluoroacetamide [ISO], monocrotophos [ISO] and phosphamidon [ISO])
2018-12-00	29241900	Acyclic amides, incl. acyclic carbamates, and their derivatives, and salts thereof (excl. meprobamate [INN], fluoroacetamide [ISO], monocrotophos [ISO] and phosphamidon [ISO])
2018-03-00	84439990	Parts and accessories of printers, copying machines and facsimile machines, n.e.s. (excl. electronic assemblies and of printing machinery used for printing by means of plates, cylinders and other printing components of heading 8442)
2018-03-00	84439990	Parts and accessories of printers, copying machines and facsimile machines, n.e.s. (excl. electronic assemblies and of printing machinery used for printing by means of plates, cylinders and other printing components of heading 8442)
2018-02-00	29371900	Polypeptide hormones, protein hormones and glycoprotein hormones, their derivatives and structural analogues, used primarily as hormones (excl. somatropin, its derivatives and structural analogues, and insulin and its salts)
2018-02-00	29371900	Polypeptide hormones, protein hormones and glycoprotein hormones, their derivatives and structural analogues, used primarily as hormones (excl. somatropin, its derivatives and structural analogues, and insulin and its salts)
2016-11-00	29371900	Polypeptide hormones, protein hormones and glycoprotein hormones, their derivatives and structural analogues, used primarily as hormones (excl. somatropin, its derivatives and structural analogues, and insulin and its salts)
2016-10-00	29371900	Polypeptide hormones, protein hormones and glycoprotein hormones, their derivatives and structural analogues, used primarily as hormones (excl. somatropin, its derivatives and structural analogues, and insulin and its salts)
2016-10-00	39269097	Articles of plastics and articles of other materials of heading 3901 to 3914, n.e.s.
2016-08-00	30029090	Toxins and similar products, e.g. plasmodia (excl. vaccines and cultures of micro-organisms)
2016-07-00	29371900	Polypeptide hormones, protein hormones and glycoprotein hormones, their derivatives and structural analogues, used primarily as hormones (excl. somatropin, its derivatives and structural analogues, and insulin and its salts)
2016-07-00	30049000	Medicaments consisting of mixed or unmixed products for therapeutic or prophylactic purposes, put up in measured doses "incl. those in the form of transdermal administration" or in forms or packings for retail sale (excl. medicaments containing antibiotics, medicaments containing hormones or steroids used as hormones, but not containing antibiotics, medicaments containing alkaloids or derivatives thereof but not containing hormones or antibiotics and medicaments containing provitamins, vitamins
2016-07-00	39072099	Polyethers in primary forms (excl. polyether alcohols, polyacetals and copolymer of 1-chloro-2,3-epoxypropane with ethylene oxide)
2016-06-00	39072099	Polyethers in primary forms (excl. polyether alcohols, polyacetals and copolymer of 1-chloro-2,3-epoxypropane with ethylene oxide)
2016-05-00	29371900	Polypeptide hormones, protein hormones and glycoprotein hormones, their derivatives and structural analogues, used primarily as hormones (excl. somatropin, its derivatives and structural analogues, and insulin and its salts)
2016-03-00	29371900	Polypeptide hormones, protein hormones and glycoprotein hormones, their derivatives and structural analogues, used primarily as hormones (excl. somatropin, its derivatives and structural analogues, and insulin and its salts)
2016-03-00	38220000	Diagnostic or laboratory reagents on a backing, prepared diagnostic or laboratory reagents whether or not on a backing, and certified reference materials (excl. compound diagnostic reagents designed to be administered to the patient, blood-grouping reagents, animal blood prepared for therapeutic, prophylactic or diagnostic uses and vaccines, toxins, cultures of micro-organisms and similar products)
2016-02-00	29371900	Polypeptide hormones, protein hormones and glycoprotein hormones, their derivatives and structural analogues, used primarily as hormones (excl. somatropin, its derivatives and structural analogues, and insulin and its salts)
2016-01-00	29420000	Separate chemically defined organic compounds, n.e.s.
2016-01-00	34042000	Poly"oxyethylene" [polyethylene glycol] waxes
2015-11-00	38220000	Diagnostic or laboratory reagents on a backing, prepared diagnostic or laboratory reagents whether or not on a backing, and certified reference materials (excl. compound diagnostic reagents designed to be administered to the patient, blood-grouping reagents, animal blood prepared for therapeutic, prophylactic or diagnostic uses and vaccines, toxins, cultures of micro-organisms and similar products)
2015-09-00	29371900	Polypeptide hormones, protein hormones and glycoprotein hormones, their derivatives and structural analogues, used primarily as hormones (excl. somatropin, its derivatives and structural analogues, and insulin and its salts)
2015-08-00	30039000	Medicaments consisting of two or more constituents mixed together for therapeutic or prophylactic uses, not in measured doses or put up for retail sale (excl. antibiotics containing hormones or steroids used as hormones, but not containing antibiotics, alkaloids or derivatives thereof, hormones or antibiotics or goods of heading 3002, 3005 or 3006)
2015-08-00	90275000	Instruments and apparatus for physical or chemical analysis, using UV, visible or IR optical radiations (excl. spectrometers, spectrophotometers, spectrographs, and gas or smoke analysis apparatus)
2015-04-01	29371900	Polypeptide hormones, protein hormones and glycoprotein hormones, their derivatives and structural analogues, used primarily as hormones (excl. somatropin, its derivatives and structural analogues, and insulin and its salts)
2015-04-00	29371900	Polypeptide hormones, protein hormones and glycoprotein hormones, their derivatives and structural analogues, used primarily as hormones (excl. somatropin, its derivatives and structural analogues, and insulin and its salts)

For goods imported into the United Kingdom, only imports originating from outside the EU are shown

Government Grants / Awards

Technology Strategy Board Awards

The Technology Strategy Board has not awarded BIODEXA PHARMACEUTICALS PLC any grants or awards. Grants from the TSB are an indicator that the company is investing in new technologies or IPR

European Union CORDIS Awards

The European Union has not awarded BIODEXA PHARMACEUTICALS PLC any grants or awards.

Ownership

We could not find any group structure information

Is this data useful to you?

If you found the data here useful, PLEASE HELP US. We are a start-up and believe in making information freely available. Please DONATE to help.
Alternatively by linking to us, posting on twitter, facebook and linkedin about us and generally spreading the word, you'll help us to grow. Our vision is to provide high quality data about the activities of all the companies in the world and where possible make it free to use and view. Finding and integrating data from thousands of data sources is time consuming and needs lots of effort. By simply spreading the word about us, you will help us.

Need more information?

We offer bespoke investigations into companies. If you need more information about this company we can gather more information as directed by you. This may, for example, be a forensic investigation such as tracing hidden assets. The engagement is on a time and materials basis. We charge GBP £ 500 per day + VAT. Contact us with a description of what you're looking for and we will assess whether we can help.

Last Datalog update:	2024-11-05 18:36:53
Primary Source:	Companies House

Company Overview

Company Officers of BIODEXA PHARMACEUTICALS PLC

Related Directorships

Trademark assignments by BIODEXA PHARMACEUTICALS PLC